These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
233 related articles for article (PubMed ID: 31695840)
61. Cyclin-Dependent Kinase Inhibitors for the Treatment of Breast Cancer: Past, Present, and Future. DiPippo AJ; Patel NK; Barnett CM Pharmacotherapy; 2016 Jun; 36(6):652-67. PubMed ID: 27087139 [TBL] [Abstract][Full Text] [Related]
62. Ribociclib for post-menopausal women with HR+/HER2- advanced or metastatic breast cancer. Zangardi ML; Spring LM; Blouin GC; Bardia A Expert Rev Clin Pharmacol; 2017 Nov; 10(11):1169-1176. PubMed ID: 28875723 [TBL] [Abstract][Full Text] [Related]
63. Ribociclib plus endocrine therapy for premenopausal women with hormone-receptor-positive, advanced breast cancer (MONALEESA-7): a randomised phase 3 trial. Tripathy D; Im SA; Colleoni M; Franke F; Bardia A; Harbeck N; Hurvitz SA; Chow L; Sohn J; Lee KS; Campos-Gomez S; Villanueva Vazquez R; Jung KH; Babu KG; Wheatley-Price P; De Laurentiis M; Im YH; Kuemmel S; El-Saghir N; Liu MC; Carlson G; Hughes G; Diaz-Padilla I; Germa C; Hirawat S; Lu YS Lancet Oncol; 2018 Jul; 19(7):904-915. PubMed ID: 29804902 [TBL] [Abstract][Full Text] [Related]
64. Mechanism of drug resistance in relation to site of metastasis: Meta-analyses of randomized controlled trials in advanced breast cancer according to anticancer strategy. Niraula S; Ocana A Cancer Treat Rev; 2016 Nov; 50():168-174. PubMed ID: 27693931 [TBL] [Abstract][Full Text] [Related]
65. Treatment of Luminal Metastatic Breast Cancer beyond CDK4/6 Inhibition: Is There a Standard of Care in Clinical Practice? Mavratzas A; Marmé F Breast Care (Basel); 2021 Apr; 16(2):115-128. PubMed ID: 34012366 [TBL] [Abstract][Full Text] [Related]
66. Successful management of bilateral orbital metastases from invasive lobular breast cancer with abemaciclib and letrozole: a case report and literature review. Rodrigues Alves N; Duarte AF; Ribeiro DF; Silva RS; Carvalho BA; Alpuim Costa D Front Oncol; 2024; 14():1286910. PubMed ID: 38322413 [TBL] [Abstract][Full Text] [Related]
67. How to Treat HR+/HER2- Metastatic Breast Cancer Patients after CDK4/6 Inhibitors: An Unfinished Story. Cogliati V; Capici S; Pepe FF; di Mauro P; Riva F; Cicchiello F; Maggioni C; Cordani N; Cerrito MG; Cazzaniga ME Life (Basel); 2022 Mar; 12(3):. PubMed ID: 35330128 [TBL] [Abstract][Full Text] [Related]
68. Use of cyclin-dependent kinase 4/6 (CDK4/6) inhibitors in older patients with ER-positive HER2-negative breast cancer: Young International Society of Geriatric Oncology review paper. Battisti NML; De Glas N; Sedrak MS; Loh KP; Liposits G; Soto-Perez-de-Celis E; Krok-Schoen JL; Menjak IB; Ring A Ther Adv Med Oncol; 2018; 10():1758835918809610. PubMed ID: 30479671 [TBL] [Abstract][Full Text] [Related]
69. Inhibiting CDK in Cancer Therapy: Current Evidence and Future Directions. Vijayaraghavan S; Moulder S; Keyomarsi K; Layman RM Target Oncol; 2018 Feb; 13(1):21-38. PubMed ID: 29218622 [TBL] [Abstract][Full Text] [Related]
70. Inhibitors targeting CDK4/6, PARP and PI3K in breast cancer: a review. Nur Husna SM; Tan HT; Mohamud R; Dyhl-Polk A; Wong KK Ther Adv Med Oncol; 2018; 10():1758835918808509. PubMed ID: 30542378 [TBL] [Abstract][Full Text] [Related]
71. Ribociclib in Breast Cancer Brain Metastases: A Case Report. Radke I; von Wahlde MK; Schülke C; Tio J Breast Care (Basel); 2020 Oct; 15(5):543-547. PubMed ID: 33224000 [TBL] [Abstract][Full Text] [Related]
72. Prognostic characteristics in hormone receptor-positive advanced breast cancer and characterization of abemaciclib efficacy. Di Leo A; O'Shaughnessy J; Sledge GW; Martin M; Lin Y; Frenzel M; Hardebeck MC; Smith IC; Llombart-Cussac A; Goetz MP; Johnston S NPJ Breast Cancer; 2018; 4():41. PubMed ID: 30588487 [TBL] [Abstract][Full Text] [Related]
73. CDK4/6 inhibitors in the treatment of patients with breast cancer: summary of a multidisciplinary round-table discussion. Preusser M; De Mattos-Arruda L; Thill M; Criscitiello C; Bartsch R; Ruhstaller T; de Azambuja E; Zielinski CC ESMO Open; 2018; 3(5):e000368. PubMed ID: 30167331 [TBL] [Abstract][Full Text] [Related]
74. Targeted Therapies for Breast Cancer Brain Metastases. Cali Daylan AE; Leone JP Clin Breast Cancer; 2021 Aug; 21(4):263-270. PubMed ID: 33384227 [TBL] [Abstract][Full Text] [Related]
75. Exclusion of Patients With Brain Metastases in Published Phase III Clinical Trials for Advanced Breast Cancer. Sharma A; Searle K; Hasan S; Chan S; Pond G; Jerzak KJ Clin Breast Cancer; 2022 Oct; 22(7):629-633. PubMed ID: 35965204 [TBL] [Abstract][Full Text] [Related]
76. Anti-angiogenetic therapies for central nervous system metastases from non-small cell lung cancer. Buttigliero C; Bertaglia V; Novello S Transl Lung Cancer Res; 2016 Dec; 5(6):610-627. PubMed ID: 28149756 [TBL] [Abstract][Full Text] [Related]
77. Abemaciclib-induced lung damage leading to discontinuation in brain metastases from breast cancer: A case report. Yamashiro H; Morii N World J Clin Cases; 2023 Dec; 11(35):8425-8430. PubMed ID: 38130622 [TBL] [Abstract][Full Text] [Related]
78. Intracranial Response Rate in Patients with Breast Cancer Brain Metastases after Systemic Therapy. Niwinska A; Pogoda K; Jagiello-Gruszfeld A; Duchnowska R Cancers (Basel); 2022 Feb; 14(4):. PubMed ID: 35205723 [TBL] [Abstract][Full Text] [Related]
79. Update Breast Cancer 2018 (Part 4) - Genomics, Individualized Medicine and Immune Therapies - in the Middle of a New Era: Treatment Strategies for Advanced Breast Cancer. Müller V; Wöckel A; Lux MP; Janni W; Hartkopf AD; Nabieva N; Taran FA; Hadji P; Tesch H; Ettl J; Lüftner D; Welslau M; Belleville E; Brucker SY; Schütz F; Fasching PA; Fehm TN; Kolberg HC; Schneeweiss A; Overkamp F Geburtshilfe Frauenheilkd; 2018 Nov; 78(11):1119-1128. PubMed ID: 30498279 [TBL] [Abstract][Full Text] [Related]